Online inquiry

IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6871MR)

This product GTTS-WQ6871MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets KLKB1 gene. The antibody can be applied in Hereditary Angioedema (HAE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000892.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3818
UniProt ID P03952
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6871MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3806MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ13764MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ42MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ14854MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ8129MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ6986MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ3016MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ5006MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA c4G7-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW